A treatment which slows the growth of colon and liver cancers

This discovery is the principal result of her doctoral dissertation, entitled “Lipo-Polymeric Vectors for the Transfer of DNA in Cancer Cells of the Colon”, which was subsidized by the Basque Government. In order to carry out the study, this scientist of the Department of Pharmacy and Pharmaceutical Technology used genetic therapy with non-viral vectors for transferring genetic material to the cancerous cells. With this technique, we can assure the therapeutic function of the drug in a wide variety of tissues. In addition, we can apply the treatment repeatedly, since it does not generate immunity, as occurs with viral vectors.

With the objective of improving the effectiveness of this methodology, the specialist worked on designing non-viral systems which act directly upon the liver and the colon. In this manner, she prepared, optimized and evaluated, in vitro and in vivo, a new pharmaceutical format called ‘lipopolyplex.’ This compound aids the genetic material in penetrating into the damaged cells, and allows drug release in tumorous organs.
500,000 deaths per year

Experimentation with the new drug in mice has shown that it slows tumor growth with respect to those animals subjected to other procedures. This diminishing of the cancerogenous area is possible, according to the scientist, thanks to the stimulation of the immune system, since the introduction of the correct gene in the diseased body can cause it to repair itself and destroy the tumor.

In addition, the researcher of the University of Navarra noted that colon cancer alone causes more than 500,000 deaths per year in the West, and currently the only effective treatment is surgery. Despite this treatment, noted the researcher, between 40 and 60% of colon cancer patients die, and for this reason it is important that we seek out treatment based on genetic therapy.

Source: Elhuyar Fundazioa

Studies spot numerous undiscovered gene alterations in pancreatic and brain cancers
HHMI investigators have detected a multitude of broken, missing, and overactive genes in pancreatic and brain tumors, in the most detailed genetic survey yet of any human tumor. Some of these genetic changes were previously unknown and could provide new leads for improved diagnosis and therapy for these devastating cancers.
Early onset gene for inflammatory bowel diseases identified
A study of Crohn's disease and ulcerative colitis in children has identified a gene that influences whether children get these diseases early in life, and points to a potential new target for treatment. The findings of the international team that performed the study were published online this week by the journal Nature Genetics.
Researchers identify gene responsible for rare childhood disease
The chromosomal abnormality that causes a rare, but often fatal, disorder that affects infants has been identified by researchers at the University of California, San Diego School of Medicine, who happened to treat two young children with the disease in San Diego – two of perhaps a dozen children in the entire country diagnosed with the disorder.
New approach to cancer: Find most tightly controlled genes
Scientists at a Duke University medical school in Singapore have found a new way to study cancer that could be very useful for developing targeted therapies against cancer and possibly many other diseases.
Tumor-inhibiting protein could be effective in treating leukemia
(PhysOrg.com) -- Angiocidin, a tumor-inhibiting novel protein discovered by Temple University researchers, may also have a role as a new therapeutic application in treating leukemia, according to a study by the researchers.
Family history of colorectal cancer linked with reduced risk of cancer recurrence
Among patients with advanced colon cancer receiving treatment that includes chemotherapy, a family history of colorectal cancer is associated with a significant reduction in cancer recurrence and death, with the risk reduced further by having an increasing number of affected first-degree relatives, according to a study in the June 4 issue of JAMA.
Researchers identify genetic markers that predict efficacy of novel cancer drug
Researchers at the University of Southern California (USC) and USC/Norris Comprehensive Cancer Center have identified genetic markers in cancer cells that predicted the benefit of a novel cancer drug prior to chemotherapy.
Combined physical and genetic map finds cancer's 'ignition key'
Whole-organ maps that superimpose genetic information over the terrain of cancerous bladders chart the molecular journey from normal cell to invasive cancer, an international research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports online at the journal Laboratory Investigation, a member of the Nature Publishing Group.

A treatment which slows the growth of colon and liver cancers

Related stories:

News discussion: